Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2011

01-11-2011 | Original paper

Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis

Authors: Jessica M. Faupel-Badger, Yuping Wang, S. Ananth Karumanchi, Frank Stanczyk, Michael Pollak, Thomas McElrath, Robert N. Hoover, Rebecca Troisi

Published in: Cancer Causes & Control | Issue 11/2011

Login to get access

Abstract

Background

The objective of this study was to comprehensively profile biological factors in pregnancy that have been postulated to be important components of the in utero environment and may also have relevance to later susceptibility to cancer and other chronic diseases.

Methods

Steroid sex hormones, IGFs, and angiogenic factors were measured in maternal and cord serum from term normotensive pregnancies. Spearman correlations and linear regression estimated relationships among the biological factors and clinical characteristics.

Results

The analytes were generally not correlated between maternal and fetal circulations. However, significant correlations were demonstrated among several analytes within maternal or cord samples. A few analytes were associated with clinical characteristics (e.g., maternal IGF-1 and IGFBP-3 were inversely correlated with offspring birth weight, while maternal leptin and cord testosterone were positively correlated with this characteristic). Maternal androgens were higher in African-Americans than whites, and maternal PlGF and soluble fms-like tyrosine kinase-1 (sFlt-1) were higher in male than female offspring.

Conclusions

There were significant correlations among analytes, but the patterns differed depending on whether they were measured in the maternal or fetal circulation. The number and magnitude of correlations among analytes, however, should affect the design and interpretation of future studies.
Literature
1.
Randhawa RS (2008) The insulin-like growth factor system and fetal growth restrictionn. Pediatr Endocrinol Rev 6:235–240PubMed
2.
Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D et al (2003) Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. Int J Epidemiol 32:455–460PubMedCrossRef
3.
Young BC, Levine RJ, Karumanchi SA (2010) Pathogenesis of preeclampsia. Annu Rev Pathol 5:173–192PubMedCrossRef
4.
Acromite MT, Mantzoros CS, Leach RE, Hurwitz J, Dorey LG (1999) Androgens in preeclampsia. Am J Obstet Gynecol 180:60–63PubMedCrossRef
5.
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP et al (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005PubMedCrossRef
6.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683PubMedCrossRef
7.
Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 194:1034–1041PubMedCrossRef
8.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658PubMed
9.
Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H et al (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50:137–142PubMedCrossRef
10.
Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H et al (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21:9–23PubMedCrossRef
11.
Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR (2005) Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 122:33–39PubMedCrossRef
12.
Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP et al (2004) First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89:770–775PubMedCrossRef
13.
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649PubMedCrossRef
14.
Salamalekis E, Bakas P, Vitoratos N, Eleptheriadis M, Creatsas G (2006) Androgen levels in the third trimester of pregnancy in patients with preeclampsia. Eur J Obstet Gynecol Reprod Biol 126:16–19PubMedCrossRef
15.
Barker DJ (1995) Fetal origins of coronary heart disease. BMJ 311:171–174PubMed
16.
17.
Troisi R, Potischman N, Hoover RN (2007) Exploring the underlying hormonal mechanisms of prenatal risk factors for breast cancer: a review and commentary. Cancer Epidemiol Biomarkers Prev 16:1700–1712PubMedCrossRef
18.
Ekbom A (1998) Growing evidence that several human cancers may originate in utero. Semin Cancer Biol 8:237–244PubMedCrossRef
19.
Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216–218PubMedCrossRef
20.
21.
Albrecht ED, Babischkin JS, Lidor Y, Anderson LD, Udoff LC, Pepe GJ (2003) Effect of estrogen on angiogenesis in co-cultures of human endometrial cells and microvascular endothelial cells. Hum Reprod 18:2039–2047PubMedCrossRef
22.
Albrecht ED, Pepe GJ (2003) Steroid hormone regulation of angiogenesis in the primate endometrium. Front Biosci 8:d416–d429PubMedCrossRef
23.
Dabrosin C (2005) Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis 8:127–136PubMedCrossRef
24.
Hyder SM, Chiappetta C, Stancel GM (2000) Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone. Cancer Lett 156:101–107PubMedCrossRef
25.
Hyder SM, Nawaz Z, Chiappetta C, Stancel GM (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60:3183–3190PubMed
26.
Shenoy V, Kanasaki K, Kalluri R (2010) Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 21:529–536PubMedCrossRef
27.
Gingery A, Bahe EL, Gilbert JS (2009) Placental ischemia and breast cancer risk after preeclampsia: tying the knot. Expert Rev Anticancer Ther 9:671–681PubMedCrossRef
28.
Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616PubMed
29.
Ray A, Cleary MP (2010) Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 14:443–451PubMedCrossRef
30.
Vona-Davis L, Rose DP (2009) Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 20:193–201PubMedCrossRef
31.
Zhang J, Masciocchi M, Lewis D, Sun W, Liu A, Wang Y (2008) Placental anti-oxidant gene polymorphisms, enzyme activity, and oxidative stress in preeclampsia. Placenta 29:439–443PubMedCrossRef
32.
Goebelsmann AE, Bernstein GS, Gale JA, Kletzky OA, Nakamura RM, Coulson AH (eds) (1979) Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. Academic Press, New York
33.
Goebelsmann U, Horton R, Mestman JH, Arce JJ, Nagata Y, Nakamura RM et al (1973) Male pseudohermaphroditism due to testicular 17 -hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 36:867–879PubMedCrossRef
34.
Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN et al (1999) Aromatase and breast cancer susceptibility. Endocr Relat Cancer 6:165–173PubMedCrossRef
35.
Scott JZ, Stanczyk FZ, Goebelsmann U, Mishell DR Jr (1978) A double-antibody radioimmunoassay for serum progesterone using progesterone-3-(O-carboxymethyl) oximino-[125I]-iodo-histamine as radioligand. Steroids 31:393–405PubMedCrossRef
36.
Katagiri H, Stanczyk FZ, Goebelsmann U (1974) Estriol in pregnancy. III. Development, comparison and use of specific antisera for rapid radioimmunoassay of unconjugated estriol in pregnancy plasma. Steroids 24:225–238
37.
Troisi R, Potischman N, Roberts JM, Harger G, Markovic N, Cole B et al (2003) Correlation of serum hormone concentrations in maternal and umbilical cord samples. Cancer Epidemiol Biomarkers Prev 12:452–456PubMed
38.
Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G et al (2009) Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. Cancer Epidemiol Biomarkers Prev 18:1484–1491PubMedCrossRef
39.
Potischman N, Troisi R, Thadhani R, Hoover RN, Dodd K, Davis WW et al (2005) Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. Cancer Epidemiol Biomarkers Prev 14:1514–1520PubMedCrossRef
40.
Park SK, Kang D, McGlynn KA, Garcia-Closas M, Kim Y, Yoo KY et al (2008) Intrauterine environments and breast cancer risk: meta-analysis and systematic review. Breast Cancer Res 10:R8PubMedCrossRef
41.
Silva Idos S, De Stavola B, McCormack V (2008) Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Med 5:e193PubMedCrossRef
42.
Xu X, Dailey AB, Peoples-Sheps M, Talbott EO, Li N, Roth J (2009) Birth weight as a risk factor for breast cancer: a meta-analysis of 18 epidemiological studies. J Womens Health (Larchmt) 18:1169–1178CrossRef
43.
Caughey RW, Michels KB (2009) Birth weight and childhood leukemia: a meta-analysis and review of the current evidence. Int J Cancer 124:2658–2670PubMedCrossRef
44.
Troisi R, Lagiou P, Trichopoulos D, Xu B, Chie L, Stanczyk FZ et al (2008) Cord serum estrogens, androgens, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 in Chinese and U.S. Caucasian neonates. Cancer Epidemiol Biomarkers Prev 17:224–231PubMedCrossRef
Metadata
Title
Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis
Authors
Jessica M. Faupel-Badger
Yuping Wang
S. Ananth Karumanchi
Frank Stanczyk
Michael Pollak
Thomas McElrath
Robert N. Hoover
Rebecca Troisi
Publication date
01-11-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 11/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9835-3

Other articles of this Issue 11/2011

Cancer Causes & Control 11/2011 Go to the issue

Original paper

Serum total and HDL cholesterol and risk of prostate cancer

Original paper

What factors do cancer patients believe contribute to the development of their cancer? (New South Wales, Australia)

Original paper

Ecological study for refrigerator use, salt, vegetable, and fruit intakes, and gastric cancer

Original paper

Social and clinical predictors of prostate cancer treatment decisions among men in South Carolina

Brief report

Insulin-like growth factor-I and C-reactive protein during pregnancy and maternal risk of non-epithelial ovarian cancer: a nested case–control study

Original paper

Regular aspirin use and breast cancer risk in US Black Women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits